ArchiveChinese herbal injections for clearing heat and invigorating blood should be used rationally under the guidance of traditional Chinese medicine theory and in accordance with the principles of evidence-based treatment, which is widely used in combination with antimicrobial agents in clinical practice. And it is commonly used for the treatment of patients in acute and critical conditions. The combination of antimicrobial agents is particularly effective in the treatment of serious infections. This article reviewed the clinical application of heat-clearing and blood-activating herbal injections combined with antimicrobial agents in the treatment of serious infections, explained the current status of research on the combination of heat-clearing and blood-activating herbal injections with antimicrobial agents in the treatment of serious infections such as sepsis, severe pneumonia. To summarize the effects such as clinical efficacy and contraindications of combining heat-clearing and blood-activating herbal injections with antimicrobial agents, and to facilitate the safe and effective use of herbal injections in clinical practice. It also provided a theoretical basis and reference for an in-depth discussion on the clinical application of heat-clearing and blood-activating herbal injections in combination with antimicrobial agents.
Bacterial drug resistance is one of the hot spots in the 21st century. At least 700 000 people die from drug-resistant bacteria causing diseases every year, and drug resistance has created a huge economic and health burden. In recent years, in order to delay the process of bacterial drug resistance, under the guidance and promotion of government policies, the scientific community and the academic community have made joint efforts. At present, a variety of new antimicrobial agents have been developed in different stages of research or have been marketed. This present article briefly reviewed the drugs that had been marketed and are in phase Ⅲ clinical studies in recent years, and mainly used for the treatment of drug-resistant bacterial infections and new non-traditional antimicrobial agent substitutes. In order to provide reference for related research and clinical application, the relevant pharmacology, clinical studies and safety of the drug were introduced.
Tuberculosis is the most common opportunistic infection in acquired immune deficiency syndrome (AIDS) patients. The treatment for AIDS patients with tuberculosis is more complicated than the tuberculosis patients without AIDS, and the success rate of treatment is not ideal. Many factors, including medication compliance, adverse drug reactions and drug interactions, will affect the treatment effect of AIDS patients with tuberculosis. This article reviewed the latest advances in the treatment of AIDS patients with tuberculosis, and briefly discussed the interaction between anti-viral and antitubercular drugs and the adverse drug reactions of coadministration, so as to provide a reference for clinical treatment.
To study the effects of micro RNA (miR)-181b on lipopolysaccharide (LPS)-induced pancreatic islet β cells proliferation, apoptosis, insulin secretion level and activation of nuclear factor (NF)-κB signaling pathway and its mechanism.
Islet β cells from MIN6 mice were randomly divided into control group, LPS group, anti-miR-NC+LPS group (transfection inhibitor control), anti-miR-181b+LPS group (transfection miR-181b inhibitor) and anti-miR-181b+NF-κB signal activator pathway phorbol myristate acetate (PMA)+LPS group (transfection miR-181b inhibitor+PMA). The cell proliferation, apoptosis, insulin secretion and the protein expression of B cell lymphoma/leukemia (Bcl)-2 protein, Bcl-2 related X protein (Bax) and NF-κB p65 were measured, respectively.
Compared with the control group, the levels of miR-181b, apoptosis rate, protein expression of Bax and NF-κB p65 in the LPS group were increased, while cell proliferation activity, Bcl-2 protein expression and insulin secretion were decreased (P<0.01). Compared with the LPS group, the level of miR-181b, apoptosis rate, Bax and NF-κB p65 protein expression in the anti-miR-181b+LPS group were decreased (P<0.01), while the cell proliferation activity, Bcl-2 protein expression and insulin secretion were slightly increased, but there was no significant differences (P>0.01). PMA could slightly reverse the effects of down-regulation of miR-181b on the proliferation, apoptosis and insulin secretion of pancreatic β cells induced by LPS, but the reverse effect was not significant.
Downregulation of miR-181b can significantly inhibit the apoptosis of islet β cells induced by LPS, but has no significant effects on their proliferation and insulin secretion, which may be related to the inhibition of NF-κB signaling.
To investigate the effects of Shaoxianyu granules on liver and spleen tissue damage and helper T cell (Th)17/regulatory T cell (Treg) immune balance in mice with immune thrombocytopenia (ITP).
Thirty C57BL/6 mice were randomly divided into control group, model group, Shaoxianyu granules low-dose group (5.85 g/kg), high-dose group (11.7 g/kg) and prednisone group (5.4 mg/kg), 6 mice in each group. The immune-related indicators, Th17 and Treg cells in each group were detected, the Th17/Treg ratio was calculated, and the morphological changes of the liver and spleen were observed.
Compared with the control group, the platelet count decreased in the model group, and the concentration of platelet-related immunoglobulin (PAIg) increased (P<0.05). Compared with the control group, the platelet count increased and the concentration of PAIg decreased in Shaoxianyu granules low-dose and high-dose groups (P<0.05). Compared with the control group, the contents of interleukin (IL)-17 and transforming growth factor (TGF)-β1 decreased in the model group, and the content of IL-10 increased (P<0.05), while the content of IL-17 and TGF-β1 increased, and the content of IL-10 decreased in Shaoxianyu granules low-dose and high-dose groups (P<0.05). Compared with the control group, the spleen tissue of the mice in the model group was disordered, the white pulp was larger, the red pulp was smaller, a large number of abnormally developed megakaryocytes were seen in the medullary cord and sinus, the liver tissue was swollen, the hepatic lobule structure disappeared, and a large number of inflammatory cells infiltrated in the portal area and the interstitium. Compared with the model group, the pathological changes of the liver and spleen in Shaoxianyu granules low and high dose groups were significantly improved, and the curative effect was equivalent to that of the prednisone group. Compared with the control group, the number of Th17 cells in the model group increased, while the number of Treg cells decreased, and the ratio of Th17/Treg increased (P<0.05). Compared with the control group, the ratios of Th17/Treg in Shaoxianyu granules low and high-dose groups decreased correspondingly (P<0.05).
Shaoxianyu granules can significantly increase the number of platelets in ITP mice, effectively control bleeding, and protect the spleen and liver tissues of ITP mice by regulating the immune balance of Th17/Treg cells.
To explore the potential mechanism of Rhizoma Cimicifugae on dermatomyositis and polymyositis by using network pharmacology and molecular docking technology.
The components and action targets of Rhizoma Cimicifugae were screened out by using the systematic pharmacology database and analysis platform of traditional Chinese medicine system. The disease genes were obtained from Genecards and Drugbank databases with "dermatomyositis" and "polymyositis" as disease keywords. Venny 2.1 was used to obtain the intersection targets, Cytoscape 3.7.1 software was used to construct the component-disease-target map, and the STRING database was used to construct protein-protein interaction network. R software was used for analysis, Gene ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed on the acting targets. Autoduck and Pymol software were used for molecular docking and visual display.
Nine active components, 60 targets, 1 247 disease targets, 13 intersection targets, 68 biological processes enriched by GO, 11 cell compositions, 23 molecular functions, and 61 KEGG enrichment pathways were obtained (P<0.05). The results of molecular docking indicated that the four active ingredients had good binding ability to the core target.
The active components of cimicic acid, deoxycimicidal hydrocarbon and stigmasterol may act on interleukin-6, tumor necrosis factor, prostaglandin endoperoxidase 2 and peroxisome proliferator activated receptors γ. It regulates the inflammation and immune response of myositis through interleukin-17, toll like receptor and retinoic acid-induced gene Ⅰ.
To analyze the efficacy and safety of icotinib hydrochloride combined with intensity-modulated radiation therapy (IMRT) in the treatment of brain metastases from epidermal growth factor receptor (EGFR) mutation-positive lung adenocarcinoma.
One-hundred cases of brain metastases patients from EGFR mutation-positive lung adenocarcinoma admitted to the first affiliated hospital of Henan university from April 2017 to April 2019 were retrospectively analyzed, and they were divided into the targeted therapy group (n=50) and the combined therapy group (n=50) according to the treatment method. The targeted therapy group were treated with icotinib hydrochloride, and the combined therapy group received IMRT treatment on the basis of the targeted therapy group. After four months of targeted therapy, the short-term curative effects of the two groups were evaluated, the occurrence of adverse reactions in the two groups were counted, the levels of serum tumor markers (carcinoembryonic antigen, carbohydrate antigen 19-9, and cytokeratin 19 fragment antigen 21-1) were detected at the time of enrollment and four months after targeted therapy, and the two-year survival rate was followed up.
The objective remission rate in the combined therapy group was 82.00%, which was significantly higher than 58.00% in the targeted therapy group (P<0.05). The adverse reactions such as rash, nausea and vomiting, fatigue, bone marrow suppression, diarrhea, liver and kidney injury in the two groups were all in the grade Ⅰ to Ⅲ, which were tolerated by the patients. There was no significant difference in the grade of adverse reactions between the two groups (P>0.05). After four months of targeted therapy, the levels of serum tumor markers in the two groups were significantly lower than those in the same group when joining the group (P<0.05), and the combined therapy group were significantly lower than those in the targeted therapy group in the same period (P<0.05). The two-year survival rate of the combined therapy group was 38.00%, which was significantly higher than that in the targeted therapy group (20.00%)(P<0.05).
Icotinib hydrochloride combined with IMRT in the treatment of brain metastasis from EGFR mutation-positive lung adenocarcinoma can achieve better short-term and long-term effects, and the adverse reactions are mild and can tolerated by the patients.
To study the efficacy and safety of propofol combined with esketamine for sedation during endoscopic retrograde cholangiopancreatography (ERCP).
A total of 100 patients who received ERCP in first hospital of Qinhuangdao from January 2020 to January 2021 were selected for prospective study. The patients were divided into group A (intravenous anesthesia with propofol combined with esketamine) and group B (intravenous anesthesia with propofol combined with fentanyl) according to the random number table method, 50 cases in each group. The scores of sedation were compared between the two groups. Heart rate, mean arterial pressure (MAP) and blood oxygen saturation (SpO2) were recorded before anesthesia (T0), after induction (T1), through oral endoscopy (T2), after surgery (T3) and after recovery (T4) in both groups. The operation time, recovery time, total dosage of propofol and the incidence of adverse reactions were compared between the two groups.
The sedation score of group A was significantly better than that of group B (P<0.05). The main effects of time and method on heart rate, MAP and SpO2 levels were significant (P<0.05). There was no interaction effect between time and method on heart rate, MAP and SpO2 levels (P>0.05). The heart rate of group A was higher than that of group B at T4 (P<0.05). MAP and SpO2 in group A were higher than those in group B at T3 and T4 (P<0.05). The time of recovery in group A was shorter than that in group B, and the dosage of propofol in group A was less than that in group B (P<0.05). The total incidence of adverse reactions in group A was lower than that in group B (P<0.05).
Esketamine combined with propofol in ERCP anesthesia can provide effective sedative and analgesic effect, has advantages in maintaining intraoperative hemodynamic stability, and can reduce the dosage of anesthetic drugs, shorten the time to wake up, and reduce the incidence of adverse reactions, which is a safe and effective anesthesia program.
To investigate the effectiveness and safety of anlotinib combined with hyperthermia chemotherapy in the second-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).
A total of 40 patients with ES-SCLC who had relapsed after the first-line treatment admitted to Harrison international peace hospital from February 2020 to June 2022 were selected and randomly divided into the observation group and control group, 20 cases in each group. The patients in the control group received hyperthermia chemotherapy with irinotecan and the patients in the observation group were treated with anlotinib based on the control group (took it for 2 weeks and stopped for 1 week). Every 3 weeks was a cycle. The efficacy and adverse reactions of the two groups were compared.
After 2 cycles of chemotherapy, total effective rate for solid tumors, disease control rate of tumors, progression-free survival (PFS) and overall survival (OS) of the observation group were higher than those of the control group (P<0.05). The serum levels of carcinoembryonic antigen, carbohydrate antigen 125, cytokeratin 19 fragment antigen 21-1, pro-gastrin-releasing peptide, neuron-specific enolase of the observation group were higher than those of the control group (P<0.05). There was no significant difference in the occurrence of adverse reactions between the two groups during chemotherapy (P>0.05). The serum levels of vascular endothelial growth factor and angiopoietin-2 of the observation group were higher than those of the control group (P<0.05).
Anlotinib combined with hyperthermia chemotherapy in the second-line treatment of patients with ES-SCLC can improve the short-term efficacy, reduce the level of serum tumor markers, inhibit tumor angiogenesis, prolong PFS and OS, and it is safe and reliable.
To observe the clinical effects of diphosphate combined with active vitamin D in the treatment of knee osteoarthritis (KOA) with osteoporosis (OP).
A total of 98 patients with KOA and OP in the department of osteoarthritis, Shuguang hospital affiliated to Shanghai university of traditional Chinese medicine from March 2015 to February 2017 were selected, and randomly divided into observation group and control group, with 49 cases in each group. The observation group was treated with diphosphate combined with active vitamin D orally, and the control group was treated with glucosamine sulfate capsules combined with active vitamin D orally. The course of treatment was 3 months. The bone mineral density (BMD), visual analog scale (VAS) scores, Western Ontario and McMaster University of Orthopedic Index (WOMAC) of the femoral neck were measured to evaluate the degree of OP and knee pain before and after treatment.
After 3 months of treatment, BMD increased in both groups, and the difference between the two groups was statistically significant (P<0.05). After 2 months of treatment, the VAS and WOMAC scores decreased between the two groups, and the difference in WOMAC scores between the two groups were statistically significant (P<0.05). After 3 months of treatment, the knee VAS scores and WOMAC of the two groups were lower than those before treatment, and the differences between the groups were statistically significant (P<0.05).
Diphosphate combined with active vitamin D has a good effect on improving KOA combined with OP, which is worthy of further clinical promotion.
To investigate the effects of nafamostat mesilate as an anticoagulant in patients at high risk of bleeding after cardiovascular surgery undergoing continuous renal replacement therapy (CRRT).
Twenty-seven patients with high risk of bleeding who underwent CRRT after cardiovascular surgery in the first affiliated hospital of naval medical university from August 2021 to April 2022 were enrolled. According to the different anticoagulants, the patients were divided into anticoagulant group (nafamostat mesilate as anticoagulant, n=12) and non-anticoagulant group (n=15). The incidence of adverse events and the service life of the filter were compared between the two groups, and the coagulation indexes of the anticoagulation group during the treatment were further analyzed.
The life of cardiopulmonary bypass through the first cannula was significantly longer than that in the non-anticoagulation group [(31.82±10.84) h vs (21.64±12.26) h, P=0.033]. The average service life of the filter during CRRT were also significantly longer than those in the non-anticoagulation group (P<0.05), Also, the incidence of bleeding events in the anticoagulation group was no increase throughout the treatment period.
It is safe and effective to use nafamostat mesilate as an anticoagulant in patients with high bleed risk after cardiovascular surgery during CRRT, which can effectively prolong the use time of the filter and no increase in the incidence of hemorrhagic complications.
To evaluate the efficacy and safety of nafamostat mesilate anticoagulation in patients treated with continuous renal replacement therapy (CRRT) in surgery intensive care unit (SICU) by retrospective study.
From January 2021 to March 2022, patients who were admitted to the department of anesthesia and critical care medicine, Xinhua hospital affiliated to Shanghai Jiao Tong university and treated with CRRT, with nafamostat mesilate (anticoagulation group) and no heparin dialysis regimen (no heparin group) were enrolled. The filter life, filter replacement rate and the incidence of extracorporeal circuit thrombosis were analyzed. The disseminated intravascular coagulation (DIC) index, platelet count, hemoglobin level, electrolytes, the occurrence of gastrointestinal bleeding, hematuria, cerebral hemorrhage and other bleeding conditions before and after CRRT in the anticoagulation group was compared, and pay attention to the cost of hospitalization and other economic indicators.
A total of 53 CRRT treatments were completed in 14 patients treated with nafamostat mesilate. A total of 67 CRRT treatments were completed in 19 patients with heparin-free anticoagulation regimen. The coagulation change rate of the filter and pipeline in the anticoagulation group was lower than that in the no heparin group (5.66% vs 17.91%, P<0.05), and the average use time of the filter was longer than that in the non-heparin group [(10.31±2.65) h vs (7.28±1.87) h, P<0.05]. The DIC index and platelet count before and after CRRT were not affected by nafamostat mesilate anticoagulation (P>0.05). In the anticoagulant group, hyperkalemia did not occur during CRRT, and the difference in serum potassium was statistically significant compared with that before treatment (P<0.05), while the difference in serum sodium and serum chloride was not statistically significant (P>0.05).
Nafamostat mesilate is a safe and effective anticoagulant for patients treated with CRRT in SICU.
To investigate the effects of dexmedetomidine on hemodynamics, immune function and stress response in patients with rectal cancer during perioperative period.
A total of 128 patients with rectal cancer who underwent radical resection in our hospital from January 2016 to February 2019 were selected and divided into observation group (n=64) and control group (n=64). In the observation group, dexmedetomidine was pumped intravenously 30 minutes before anesthesia induction until the end of the operation. Patients in the control group were given the same amount of normal saline. Other anesthesia methods were the same as those in the observation group. Heart rate (HR), mean arterial pressure (MAP), peripheral oxygen saturation (SpO2), T-lymphocyte subsets (CD3+, CD4+, CD8+ and CD4+/CD8+) and natural killer (NK) cells were recorded before anesthesia induction (T1), immediately after surgery (T2), 30 minutes after surgery (T3) and 24 hours after surgery (T4). The levels of cortisol (CO), plasma epinephrine and norepinephrine were measured by enzyme-linked immunosorbent assay.
Compared with T1, HR at T2 and T3 in the observation group was significantly slowed down and MAP was significantly decreased. However, the HR at T2 and T3 in the control group was significantly accelerated, and the MAP was significantly increased, The levels of HR and MAP at T2 and T3 time points in the study group were lower than those in the control group, and the differences between the two groups were statistically significant (P<0.013). The change of HR at T1 to T4 in the observation group was lower than those in the control group (P<0.05). Compared with T1 time point, the levels of CD3+, CD4+ and NK cells at T2, T3 and T4 time points in the two groups decreased (P<0.013); The levels of CD4+/CD8+ at T2, T3 and T4 time points in the control group decreased (P<0.013); CD4+/CD8+ in the observation group increased at T2 time point, while T3 and T4 time points decreased (P<0.013); The levels of CD3+, CD4+, CD8+, CD4+/CD8+ and NK cells in the observation group at T2 to T4 were higher than those in the control group (P<0.013). Compared with time point T1, the blood glucose, plasma adrenaline and noradrenaline levels at time points T2 to T4 in the control group increased (P<0.013). The levels of blood glucose, CO, plasma adrenaline and noradrenaline at T2 to T4 time points in the observation group were lower than those in the control group (P<0.013).
Dexmedetomidine can effectively maintain the stability of perioperative hemodynamics in patients with rectal cancer, improve cellular immune function, significantly reduce perioperative stress response and promote postoperative recovery of patients.
To investigate the anesthetic effects of dexmedetomidine assisted general anesthesia in radical gastrectomy for gastric cancer and its effect on phosphofructokinase (PFK) and aldose reductase (AR), glucose-6-phosphate dehydrogenase (G6PD) and hemodynamics.
A total of 101 patients who underwent radical gastrectomy in Qingdao municipal hospital from December 2018 to December 2020 were retrospectively analyzed. The patients were divided into observation group (51 cases) and control group (50 cases) according to the anesthesia method. The control group was given conventional general anesthesia, while the observation group was given dexmedetomidine before induction of anesthesia. The anesthetic effect, PFK, AR, G6PD, heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), ventilation time, feeding time, getting out of bed time, postoperative hospital stay and complications before and after operation were compared between the two groups.
The total excellent and good rate of the observation group (96.08%) was higher than that of the control group (82.00%), and the difference was statistically significant (P<0.05). After operation, serum PFK in the two groups decreased with time, and the observation group was higher than that in the control group (P<0.05). The levels of AR and G6PD in the two groups increased with time, and the observation group were lower than those in the control group (P<0.05). HR, SBP and DBP of the two groups were decreased with time, and the observation group were higher than those of the control group (P<0.05). The ventilation time, fluid feeding time, getting out of bed time and postoperative hospital stay in the observation group were lower than those in the control group, and the differences were statistically significant (P<0.05). The total incidence of complications in the observation group and the control group were 1.96% and 16.00%, respectively, and the difference was statistically significant (P<0.05).
The application of dexmedetomidine in patients undergoing radical gastrectomy has a significant effect, which can improve PFK, AR, G6PD and hemodynamics, and is safe and effective.
To systematically evaluate the effectiveness and safety of secukinumab in the treatment of psoriatic arthritis (PA).
Relevant literature on the treatment of PA with secukinumab were searched in English databases (PubMed, MEDLINE, Embase, Cochrance Library) and the Chinese databases (CNKI, VIP, Wanfang), from January 2000 to December 2020. After quality evaluation of the literatures that met the inclusion criteria, the meta analysis was conducted with Revman 5.4 software.
A total of 5 randomized controlled studies involving 2 455 patients with PA were included for analysis. Meta analysis results showed that compared with the treatment of the placebo group, the treatment group with secukinumab significantly improved the patients' remission of American College of Rheumatology (ACR) by 20%[odds ratio (OR)=4.40, 95% confidence interval (CI)(3.79, 5.11), P<0.000 01], ACR50 [OR=5.84, 95%CI (4.82, 7.07), P<0.000 01], ACR70[OR=7.98, 95%CI (5.64, 11.27), P<0.000 01], psoriatic area and severity index (PASI) 75[OR=9.72, 95%CI (6.68, 14.14), P<0.000 01] and PASI90[OR=7.75, 95%CI (4.92, 12.22), P<0.000 01]. Compared with the 150 mg group, the ACR20 in 300 mg secukinumab group was significantly improved [OR=1.36, 95%CI (1.04, 1.76), P=0.02]. In terms of safety, there was no significant difference in the incidence of overall adverse events and serious adverse events between the secukinumab group and the placebo group (P>0.05). The incidence of candida infection and tumor in the secukinumab group was significantly higher than that in the placebo group [OR=2.29, 95%CI (1.18, 4.46), P=0.01, OR=3.38, 95%CI (1.20, 9.53), P=0.02].
The efficacy and safety of secukinumab in the treatment of PA skin lesions and joint lesions are reliable. However, since secukinumab has just been marketed in China, there is no long-term clinical research report, and a large number of clinical studies and further verification are needed in the future.
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) is a new class of hypoglycemic drugs, which is increasingly important in the treatment of type 2 diabetes mellitus (T2DM) due to its outstanding effects of hypoglycemia, weight loss and low risk of hypoglycemia. Over the past several years, the developer has completed seven cardiovascular outcome trial (CVOT) involving liraglutide, once-weekly long-acting exenatide, lixisenatide, abirlutide, duraglutide, semaglutide as a subcutaneous injection, and semaglutide as an oral formulation. The cardiovascular outcomes of all GLP-1 RAs were found to be noninferior to placebo, and some GLP-1 RAs were found to be superior. The results of these trials have changed national guidelines for medical treatment of T2DM. This article reviewed 7 CVOTs of GLP-1 RAs, in order to provide more support for clinical medication.
Psoriasis is a chronic inflammatory skin disease, with erythema, scales as the main clinical manifestations, long course of disease, lingering difficult to recover. Curcumin, a phenolic substance extracted from the traditional Chinese medicine Rhizoma Curcumae Longae, which has anti-inflammatory, antioxidant and anti-tumor effects, and has certain therapeutic effects on psoriasis. Due to the limitations of curcumin such as low oral administration availability and poor permeability of traditional topical administration, in order to improve the utilization rate of curcumin and expand its application in chronic skin diseases such as psoriasis, the studies of curcumin local delivery system have become a hot topic. This paper mainly reviewed the mechanism of curcumin in the treatment of psoriasis and summarized the research progress on the local drug delivery system of curcumin, so as to provide reference for further research on curcumin.
This paper introduced the definition of adherence (including medication, exercise, diet, and etc.), and illustrates the loss from non-adherence and the gains from improved adherence by taking diabetes mellitus and hypertension as examples. Based on the analysis of previous literature, this paper summarized some main experiences and lessons, and identifies five major factors influencing adherence: social and economic, health care system, therapy-related factor, condition-related factor and patient-related factor. Based on the roles of medical institutions, medical staff, pharmaceutical companies and payers, this paper discussed how to play their own advantages in their respective areas to better integrate multidisciplinary practices and coordinate actions to improve adherence. It also called on experts, academics and industry institutions to actively develop relevant standards for adherence management, regulate medical practices, and enhance the value of treatment and patient outcomes.